FMP

FMP

Enter

BCDA - BioCardia, Inc.

Profile of BioCardia, Inc.(BCDA), BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived

About

ceo

Dr. Peter A. Altman Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.biocardia.com

exchange

NASDAQ

Description

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

CIK

0000925741

ISIN

US09060U5074

CUSIP

09060U507

Address

320 Soquel Way

Phone

650 226 0120

Country

US

Employee

30

IPO Date

Nov 13, 1996

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep